Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection

J Clin Oncol. 2011 Jun 20;29(18):e543-5. doi: 10.1200/JCO.2011.34.6460. Epub 2011 Apr 11.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Asymptomatic Diseases
  • Bone Marrow / pathology
  • Carrier State / drug therapy*
  • Cell Transformation, Viral
  • Disease Progression
  • Female
  • Genes, bcl-2
  • Hepatitis B / complications
  • Hepatitis B / drug therapy*
  • Hepatitis B virus / pathogenicity
  • Humans
  • Lamivudine / therapeutic use*
  • Lymphoma, B-Cell / complications*
  • Lymphoma, B-Cell / genetics
  • Lymphoma, B-Cell / virology
  • Lymphoma, Follicular / complications*
  • Lymphoma, Follicular / genetics
  • Lymphoma, Follicular / virology
  • Middle Aged
  • Neoplasm, Residual
  • Remission Induction
  • Splenic Neoplasms / complications*
  • Splenic Neoplasms / genetics
  • Splenic Neoplasms / virology

Substances

  • Antiviral Agents
  • Lamivudine